Liquidia Technologies (LQDA)
(Delayed Data from NSDQ)
$20.31 USD
+0.24 (1.20%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $20.35 +0.04 (0.20%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Liquidia Technologies, Inc.'s return on equity, or ROE, is -177.91% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.08%. While this shows that LQDA has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
LQDA 20.31 +0.24(1.20%)
Will LQDA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LQDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LQDA
Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates
Insmed Stock Jumps 29% on Encouraging PAH Study Results
LQDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Liquidia Technologies (LQDA) Surges 13.2%: Is This an Indication of Further Gains?
Other News for LQDA
Liquidia Corp (LQDA) Announces Upcoming Second Quarter 2025 Financial Results | LQDA stock news
Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025 | LQDA ...
Liquidia (LQDA) Shares Drop Amid Legal Battle with United Therapeutics
United Therapeutics up 7%, Liquidia down 9% in afternoon trading
Bleecker Street Research short United Therapeutics, long Liquidia